company background image
RGC

Regencell Bioscience Holdings NasdaqCM:RGC Stock Report

Last Price

US$32.14

Market Cap

US$418.2m

7D

-1.6%

1Y

257.1%

Updated

09 Aug, 2022

Data

Company Financials
RGC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

RGC Stock Overview

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company.

Regencell Bioscience Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Regencell Bioscience Holdings
Historical stock prices
Current Share PriceUS$32.14
52 Week HighUS$59.00
52 Week LowUS$6.00
Beta0
1 Month Change-15.42%
3 Month Change32.70%
1 Year Change257.11%
3 Year Changen/a
5 Year Changen/a
Change since IPO206.10%

Recent News & Updates

Shareholder Returns

RGCUS PharmaceuticalsUS Market
7D-1.6%-0.8%0.3%
1Y257.1%1.5%-13.5%

Return vs Industry: RGC exceeded the US Pharmaceuticals industry which returned 2% over the past year.

Return vs Market: RGC exceeded the US Market which returned -13% over the past year.

Price Volatility

Is RGC's price volatile compared to industry and market?
RGC volatility
RGC Average Weekly Movement13.0%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement7.9%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: RGC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: RGC's weekly volatility has decreased from 44% to 13% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201414Yat-Gai Auhttps://www.regencellbioscience.com

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Regencell Bioscience Holdings Fundamentals Summary

How do Regencell Bioscience Holdings's earnings and revenue compare to its market cap?
RGC fundamental statistics
Market CapUS$418.23m
Earnings (TTM)-US$4.60m
Revenue (TTM)n/a

0.0x

P/S Ratio

-90.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
RGC income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$4.60m
Earnings-US$4.60m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.35
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio6.9%

How did RGC perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is RGC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RGC?

Other financial metrics that can be useful for relative valuation.

RGC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-90.3x
PEG Ration/a

Price to Book Ratio vs Peers

How does RGC's PB Ratio compare to its peers?

RGC PB Ratio vs Peers
The above table shows the PB ratio for RGC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.9x
TARS Tarsus Pharmaceuticals
3.1x53.2%US$463.6m
VRNA Verona Pharma
4.8x56.7%US$605.5m
JUSH.F Jushi Holdings
1.9x-40.3%US$391.7m
OCUL Ocular Therapeutix
5.7x62.7%US$377.9m
RGC Regencell Bioscience Holdings
21.2xn/aUS$418.2m

Price-To-Book vs Peers: RGC is expensive based on its Price-To-Book Ratio (21.2x) compared to the peer average (3.9x).


Price to Earnings Ratio vs Industry

How does RGC's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Book vs Industry: RGC is expensive based on its Price-To-Book Ratio (21.2x) compared to the US Pharmaceuticals industry average (2x)


Price to Book Ratio vs Fair Ratio

What is RGC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RGC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio21.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RGC's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of RGC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RGC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RGC's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Regencell Bioscience Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Regencell Bioscience Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of RGC’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Regencell Bioscience Holdings performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-442.8%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: RGC is currently unprofitable.

Growing Profit Margin: RGC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if RGC's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare RGC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RGC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).


Return on Equity

High ROE: RGC has a negative Return on Equity (-23.72%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Regencell Bioscience Holdings's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: RGC's short term assets ($19.0M) exceed its short term liabilities ($1.4M).

Long Term Liabilities: RGC has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: RGC's net debt to equity ratio (6.6%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if RGC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if RGC has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RGC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is Regencell Bioscience Holdings's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate RGC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RGC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RGC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RGC's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as RGC has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure


CEO

Yat-Gai Au (49 yo)

no data

Tenure

Mr. Yat-Gai Au serves as the Chief Financial Officer of Armitage Technologies Holding Ltd. Mr. Au served as Compliance Officer and Executive Director of Armitage Technologies Holding Ltd. He joined Armitag...


Leadership Team

Experienced Management: RGC's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: RGC's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RGC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.9%.


Top Shareholders

Company Information

Regencell Bioscience Holdings Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Regencell Bioscience Holdings Limited
  • Ticker: RGC
  • Exchange: NasdaqCM
  • Founded: 2014
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$418.234m
  • Shares outstanding: 13.01m
  • Website: https://www.regencellbioscience.com

Number of Employees


Location

  • Regencell Bioscience Holdings Limited
  • First Commercial Building
  • 11th Floor
  • Causeway Bay
  • KY1-1107
  • Hong Kong

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/09 00:00
End of Day Share Price2022/08/09 00:00
Earnings2021/12/31
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.